NFE2L2 and breast carcinoma: In these cancer cells, the active phosphorylated form of STAT3 interacts directly with the Neh1 and Neh3 domains of NFR2, and the concurrent binding of STAT3 and NRF2 to IL23A promoter accelerates breast cancer cells growth [72].